Brain implant that learns: new hope for Parkinson's?
NCT ID NCT07216976
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This study tests an adaptive deep brain stimulation (aDBS) system that automatically adjusts stimulation based on real-time brain signals. It aims to improve symptom control for 62 people with Parkinson's disease in China who already have a compatible brain implant. The main goal is to see if aDBS can maintain or increase 'good on' time (symptom relief without troublesome movements) compared to standard continuous stimulation.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Adaptive deep brain stimulation (aDBS) device
- What this could lead to
- If successful, this could offer a more personalized, responsive way to manage Parkinson's symptoms, potentially improving daily function without increasing side effects.
- What could go wrong
- This is a small, early-stage study (62 people) focused on feasibility and short-term outcomes. The adaptive algorithm may not work for everyone, and benefits over standard stimulation are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
61 people
The number who actually took part.
- Started
-
Nov 2025
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Subjects must meet all general inclusion/exclusion criteria (as assessed at the Enrollment Visit) 2. Subjects must meet the LFP screening inclusion criterion (as assessed at the LFP Screening Visit) General (Assessed at Enrollment Visit): 1. Subject has idiopathic Parkinson's disease 2. Subject is implanted (\>3 months prior to enrollment for new INS implants or \>1 month from INS replacement) with a Percept PC (Model B35200) or Percept RC (Model B35300) and Medtronic DBS leads (Model 3387, 3389, B33005 or B33015) and extensions (Model 37086 or B34000) bilaterally in the same target (physician confirmed), STN or GPi 3. In the opinion of the investigator, the subject responds to DBS Therapy. 4. Based on the opinion of the investigator, the subject's cDBS parameters and PD medications are stable (no changes within the last 4 weeks) and expected to remain stable from enrollment through the end of the aDBS Evaluation Phase 5. Subject is configured to monopolar or dual monopolar stimulation using contacts 1 and/or 2 (9 and/or 10) on at least one side 6. Subject is willing and able to attend all study-required visits and complete the study procedures (e.g. 1-month recall questionnaires, MDS-UPDRS III, Off stim/Off med visit) 7. Subject (or legally authorized representative) has the ability to understand and provide written informed consent for participation in the study prior to the study-related procedures being conducted 8. Subject is a male or non-pregnant female. If female of child-bearing potential, and if sexually active, must be using, or agree to use, a medically-acceptable method of birth control as confirmed by the investigator LFP Screening Inclusion Criteria (Conducted during LFP Screening Visit): 1\. Subject has Alpha - Beta band (8-30 Hz) amplitude ≥ 1.2 μVp detected on either left and/or right DBS leads on sensing channels 0-2, 0-3, 1-3, 8-10, 8-11, or 9-11. Exclusion Criteria: General (Assessed at the Enrollment Visit): 1. Subject and/or caregiver is unable to utilize the patient programmer 2. Subject has more than one lead in each hemisphere of the brain 3. Subject has cortical leads or additional unapproved hardware implanted in the brain 4. Subject has more than one INS 5. At enrollment, the subject's INS has a predicted battery life of \<1 year 6. Subject has Beck Depression Inventory II (BDI-II)\>25 7. Subject requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT) 8. Subject has a metallic implant in the head, (e.g., aneurysm clip, cochlear implant) 9. Subject has, or plans to obtain, an implanted electrical stimulation medical device anywhere in the body (e.g., cardiac pacemaker, defibrillator, spinal cord stimulator) 10. Subject has, or plans to obtain, an implanted medication pump for the treatment of Parkinson's disease (e.g., DUOPATM infusion pump) and/or portable infusion pump 11. Based on the opinion of the investigator, the subject has an abnormal neurological examination that would preclude them from study participation 12. Subject is breast feeding 13. Subject is under the age of 18 years 14. Subject is currently enrolled in or plans to enroll in any concurrent drug and/or device study that may confound the results of this study as determined by the Medtronic study team 15. Subjects with signal artifact on all 6 aDBS sense pathways (3 each on both DBS leads) which preclude the clinician from setting thresholds
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital
Shanghai, Shanghai Municipality, China
-
Ruijin Hospital
Shanghai, Shanghai Municipality, China
-
Sun Yat-sen Hospital
Guangzhou, Guangdong, China
-
West China Hospital
Chengdu, Sichuan, China
-
Xuanwu Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Walking memory tests may reveal early Parkinson's clues
- Colon tissue may hold clues to telling Parkinson's apart from Look-Alike diseases
- A genetic roadmap for Parkinson's: testing thousands to unlock clues
- Can gentle touch therapy calm Parkinson's tremors?
- Stem cell infusions aim to slow Parkinson's progression
- Can an inhaled levodopa ease Parkinson's OFF episodes? a study asks patients.